LOT IP05062439

CAS Number 170851-70-4

PubChem CID 9831659

Molecular Weight 711.9 g/mol

Molecular Formula C38H49N9O5

Synonyms NNC-260161, NNC 26-0161, NNC-26-0161, NCGC00167295-01, AS-56185

Storage (Lyophilized)

At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years

This product is sold as a pure compound for research purposes only, unless prescribed by a licensed physician. This product comes in the form of lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Please refer to our terms and conditions prior to purchase.

Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.

The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.

1. A Giustina, JD Veldhius, Pathophysiology of the neuro regulation of growth hormone secretion in experimental animals and the human, Endocrinology, 1 December 1998.
2. David E. Beck et al., Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients, International Journal of Colorectal Disease, 2014.
3. K. Raun et al., Ipamorelin, the first selective growth hormone secretagogue, Endocrinology, November 1998.
4. P.B Johansen et al, Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats, Growth Hormone IGF Research, April 1999.
5. Gobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999).
6. Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283.
7. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metabolism, Jul 1998; 83(7):2355-60.
8. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S15.